Wetenschap als onderneming
Kritische Succesfactoren Viroclinics Biosciences BV Toegang tot State of the Art faciliteiten Reputatie Institute of Virology
Kritische Succesfactoren Kennisbasis ErasmusMC Virologie
Halffabrikaten van andere marktpartijen
Boven op trends in onderzoek zitten door participatie in review commitees en Industrial Advies Committees
Adviseur in farmabedrijven
Farmaceutische industrie
State of the Art faciliteiten Onderzoek doen in heel de wereld: daar zijn waar virussen vandaan komen; met je neus bovenop de bron van de problemen staan
Boven op trends in onderzoek zitten door participatie in review commitees
Institute of Virology
Klinische praktijk Erasmus MC en Wereldwijd
- Diagnostische Tools - Interventies
Onderzoeksinkomsten door valorisatie via Viroclinics Durven voor-investeren Multidisciplinair & middelgroot team
1st person to call (with e.g. SARS) => toppositie versterkt zich
Kritische Succesfactoren Kennisbasis State of the Art faciliteiten Onderzoek doen in heel de wereld: daar zijn waar virussen vandaan komen; met je neus bovenop de bron van de problemen staan Boven op trends in onderzoek zitten door participatie in drafting, review en industriele advies committees Onderzoeksinkomsten door valorisatie via Viroclinics Biosciences BV Durven voor-investeren Multidisciplinair & middelgroot team met “prima donna`s”
State of the Art facilities Department Virology
State of the Art viro-, mol-, imunno-, pathoanimal labs High containment labs up to Class 3++ Professional grant writing and management Legal & patenting support (lawyers on site)
Follow trends and participate in drafting/review commitees and SAB`s Drafting committees (lobbying, EU DG`s, MEP`s…) EU: FP7, HORIZON… Review commitees EU: FP7, ERC … National (NL, CH, S, D, F, UK, USA…) SAB`s All major pharma companies (diagnostic, antiviral, vaccine…) Nationally funded programmes (NL, CH, S, D, F, HK, China…) Foundations etc (Natl and Internatl: numerous)
Worldwide vigilance, “quick on the ballness” with virus discovery setting • • • • • • • • • • • • • • • •
1995 1996 1997 1997 1998 1999 2000 2002 2003 2003 2004 2005 2008 2009 2010 2011
CDV as the cause of mass mortality in Serengeti lions -herpesvirus in seals (phocid herpesvirus-2) monk seal morbilliviruses (MSMV-WA/G) influenza A (H5N1) virus in humans lentivirus from Talapoin monkeys (SIVtal) influenza B virus in seals human metapneumovirus (hMPV) re-emerging PDV in Europe SARS CoV cause of SARS in humans (Koch`s postulates) influenza A (H7N7) virus in humans fourth human coronavirus (CoV NL) H16 influenza A viruses (new HA!) in black headed gulls dolphin herpesvirus deer astrovirus human astrovirus, human picobirnavirus ferret coronavirus, porcine picobirnavirus, stone marten anellovirus. influenza A (H1N1) virus in dogs…
Virus discovery - expertise required • • • •
Clinical diagnosis Pathology Epidemiology Laboratory classical virology electron microscopy serology animal models novel molecular techniques •family specific degenerate PCR analyses •random PCR analyses •“pathogen chips” •metagenomic sequencing
Order Mononegavirales, family Paramyxoviridae: “discovery of another human paramyxovirus” v.d.Hoogen et al., Nat.Med. 2001 (classical virology combined with random priming)
Morbillivirus
DNA Maximum likelihood, Polymerase ORF
PDVRPV CDV TuV MV Henipahvirus
Paramyxovirinae
HeV NiV
hPIV3 bPIV3 SeV
Respirovirus
hPIV1
Pneumovirinae
Pneumovirus
NDV Avulavirus
hRSV bRSV LPMV
Metapneumovirus APV 0.1
hMPV
MuV Rubulavirus SV5 hPIV2 SV41 16-10-2001
MRCA of APV and HMPV: about 200 years ago
Newly discovered human paramyxovirus hMPV - Risk groups -
- (Young) children ~10 % of children with RTI - Immunocompromised individuals (fatal cases!) - Elderly - Normal individuals ~5 % of RTI in community surveillance studies v.d.Hoogen et al., Nat.Med. 2001 Osterhaus and Fouchier, The Lancet 2003 v.d. Hoogen et al., JID 2003 Williams, J. NEJM 2004. Williams, J. J Inf Dis 2006
…
SARS-CoV - Phylogeny -
Drosten et al., NEJM 2003 Rota et al., Science 2003 v.d. Hoek et al., Nature Med., 2004 Fouchier et al., PNAS 2004 Woo et al., J.Virol., 2005
16-10-2001
hMPV as the cause?
Emerging or newly identified respiratory viruses in last 13 years - AIV`s * influenza virus - Hendra-/NipahV paramyxovirus - hMPV * paramyxovirus - SARS-CoV * coronavirus - HCoV-NL63 * coronavirus - HCoV-HKU1 coronavirus - HBoV parvovirus - KI/WU-PyV polyomavirus - MelV (KamV) orthoreovirus - H1N1v influenza virus - animal origin * ErasmusMC involvement
1997… 2000… 2001 2003 2004 2005 2005 2007 2007 (2009) 2009
“Koch postulates”
April 16, 2003 WHO Geneva Press conference of
SARS etiology network “Koch postulates”
Official declaration of SARS-CoV as the etiologic agent
Short- and mid-term objectives: - clarification of transmission routes and natural history - establishment and evaluation of diagnostic tools
Department of Virology -The team leaders – “prima donna`s” Prof. Dr. R.A.M. Fouchier
Mol.Virology
Prof. Dr. T. Kuiken
Comp.Pathology
Prof. Dr. M. Koopmans
Epidemiology
Prof. Dr. C.A.B. Boucher
Antiviral research
Dr.A.van der Eijk / Dr.P.Fraaij Dr.E.van Gorp
Clinical research “
“
Prof.Dr. G.F. Rimmelzwaan
Immunology
Dr. M. Schutten
Diagnostics
Dr. A. Andeweg
Genomics
Public-Private-Partnerships Erasmus MC Vincent Munster Emmie de Wit Debby van Riel Theo Bestebroer Ger van der Water Geert van Amerongen Robert Dias d’Ullois Marion Koopmans Martin Schutten Jan de Jong Charles Boucher Annemiek van der. Eijk Pieter Fraaij Eric van Gorp Guus Rimmelzwaan Bart Haagmans Saskia Smits Thijs Kuiken Ron Fouchier
VIRGO-FES (NL) NWO (NL) EU FP-7 NIH (USA) ViroNovative BV James Simon Viroclinics BV Koert Stittelaar Leon de Waal Edwin Veldhuis Sanofi Pasteur GSK Roche Novartis Solvay (ABBOTT) Nobilon (MSD) Crucell et al
Public-Private-Partnerships Erasmus MC Vincent Munster Emmie de Wit Debby van Riel* Theo Bestebroer Ger van der Water Geert van Amerongen* Robert Dias d’Ullois Marion Koopmans Martin Schutten* Jan de Jong* Charles Boucher Annemiek van der. Eijk Pieter Fraaij Eric van Gorp Guus Rimmelzwaan* Bart Haagmans Saskia Smits* Thijs Kuiken Ron Fouchier Ab Osterhaus* * Also VCB
*Also EMC
VIRGO-FES (NL) NWO (NL) EU FP 4-7, ERC NIH (USA) Foundations ViroNovative BV Eric Claassen* Viroclinics BV Eric Claassen* Koert Stittelaar Leon de Waal Edwin Veldhuis* Sanofi Pasteur GSK Roche Novartis Solvay (ABBOTT) Nobilon (MSD) Crucell… et al
16-10-2001
